Company: TELO
Filing Date: 2025-10-08
Form Type: 8-K
Source: 0001493152-25-017422
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-10-08
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

New
findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to
cell death through iron-dependent regulation.

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO)

In
laboratory studies using human triple-negative breast cancer cells, Telomir-1 produced a clear, concentration-dependent reduction in
cancer cell survival. As Telomir-1 concentrations increased, more cancer cells lost their ability to grow and survive. When iron was
added back to the system, the cells recovered, confirming that the compound’s activity is linked to the regulation of cellular
iron and energy balance.

The
iron dependency observed in this study is significant because aggressive cancer cells, such as those found in TNBC, are among the most
metabolically active of all breast cancer types. These cells depend on iron to support their rapid growth and survival, and iron metabolism
contributes directly to this aggressive behavior. By disrupting that iron-driven process, Telomir-1 appears to exploit a core metabolic
weakness unique to these tumors. This selectivity is important because normal cells manage iron differently and are less dependent on
it, suggesting that Telomir-1 may preferentially affect cancer cells while sparing healthy tissue.

Telomir-1
has previously been shown to reset abnormal DNA methylation patterns and restore balanced gene expression in models of cancer and age-related
disease. In TNBC, certain iron-dependent enzymes - known as Jumonji domain histone demethylases (KDMs), including KDM5A/B and KDM6B - are
thought to drive gene expression changes that make cancer cells more aggressive and resistant to therapy. The new findings suggest that
Telomir-1’s observed effects on energy regulation and iron balance may stem from its ability to influence these same epigenetic
mechanisms. Many aggressive cancers show methylation changes that activate pathways controlling iron use, oxidative stress, and energy
metabolism. By helping to restore normal epigenetic control, Telomir-1 may indirectly rebalance these pathways, offering new insight
into its broader mechanism of action.

The
Company plans to expand these studies to include additional cancer types, such as pancreatic and leukemia models, and to conduct further
animal studies in